Zobrazeno 1 - 10
of 31
pro vyhledávání: '"J.S. Pillar"'
Autor:
Molly A. McGlynn, Matthew Frank Brown, Stacie P. O'Sullivan, Anthony Marfat, John B. Cheng, Theodore E. Liston, John W. Watson, J.S. Pillar, David B. Damon, J.T. Shirley, R. J. Chambers, Gerard Antognoli, Brian S. Owens
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:2451-2456
Exploration of the indole nitrogen region of Zafirlukast (1) has uncovered a potent series of cysteinyl leukotriene D4 (LTD4) antagonists. These studies showed that a variety of functionality could be incorporated in this region of the molecule witho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ca40ed0f31d3457b3dd5a3ad8f6482
https://doi.org/10.1016/s0960-894x(98)00442-9
https://doi.org/10.1016/s0960-894x(98)00442-9
Publikováno v:
Journal of Biological Chemistry. 273:15559-15564
We have cloned and characterized the first human isozyme in a new family of cyclic nucleotide phosphodiesterases, PDE9A. By sequence homology in the catalytic domain, PDE9A is almost equidistant from all eight known mammalian PDE families but is most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815b48beb6a6c2a476da7e68bb28cba3
https://doi.org/10.1074/jbc.273.25.15559
https://doi.org/10.1074/jbc.273.25.15559
Autor:
Peter F. Moore, A. Nagahisa, Saul B. Kadin, Francis J. Sweeney, Thomas J. Carty, P. P. Pazoles, M. J. Ernest, J. D. Cheng, J.S. Pillar, Leland D. Loose, P. A. Joseph, R. J. Griffiths, S. Murase, James D. Eskra
Publikováno v:
Inflammation Research. 46:168-179
Objective and Design: The effect of tenidap on the metabolism of arachidonic acid via the 5-lipoxygenase (5-LO) pathway was investigated in vitro and in vivo.¶Materials and Treatment: In vitro (cells). Arachidonic acid (AA) stimulated rat basophilic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f48ee785de3afc195501f0a661061e05
https://doi.org/10.1007/s000110050163
https://doi.org/10.1007/s000110050163
Autor:
G.W. Antognoli, J.T. Shirley, A. Marfat, C.F. Wright, Thomas J. Carty, Frank W. Rusek, J. W. Watson, J. Delehunt, B. A. Naclerio, James F. Eggler, J.S. Pillar, Herbert Sherman, E.G. Andrews, Francis J. Sweeney, K. W. Freiert, R. Breslow, C. J. Mularski, V. L. Cohan, C J Pazoles, Lawrence S. Melvin, L.A. Rappach, John B. Cheng, David B. Damon, Jeanene E. Tickner, Judith L. Collins, P. Reiche, Hiroko Masamune, M. P. Carta, James D. Eskra, Hada William Andrew, R. J. Chambers
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1365-1370
The development of two novel LTD 4 receptor antagonists as clinical candidates for the treatment of asthma is described. The first generation compound, CP-80,798, was found to be a balanced 5-lipoxygenase inhibitor (5-LOI)/LTD 4 antagonist (LTD 4 -A)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a5fced5f481925dbd55bd727448996c
https://doi.org/10.1016/0960-894x(95)00225-i
https://doi.org/10.1016/0960-894x(95)00225-i
Autor:
Hiroko Masamune, J.T. Shirley, A. Marfat, John B. Cheng, Henry J. Showell, James F. Eggler, J.S. Pillar, Maryrose J. Conklyn, Jeanene E. Tickner, Lawrence S. Melvin, R. Breslow
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:887-892
The development of novel LTB 4 antagonists from a class of quinolylmethyl LTD 4 antagonists is described. These α-methyl quinolylmethyl chromanols were found to have good vitro activity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08bc619e3458f6601bd9c56e28f19264
https://doi.org/10.1016/0960-894x(95)00135-g
https://doi.org/10.1016/0960-894x(95)00135-g
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 34:1147-1156
The 125I analog of MK-0591, 1, has been prepared for use as a radioligand for developing a 5-lipoxygenase activating protein (FLAP) binding assay. The radiosynthesis involves a two step oxidative iododestannylation-saponification procedure. A FLAP bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da5c461102d8ccef47658358a0dcff36
https://doi.org/10.1002/jlcr.2580341204
https://doi.org/10.1002/jlcr.2580341204
Autor:
John W. Watson, Anthony Marfat, John B. Cheng, J.T. Shirley, R. J. Chambers, G.W. Antognoli, J.S. Pillar
Publikováno v:
ChemInform. 29
By addressing the issues of potency and metabolism in 3, a new series of LTD4 antagonists represented by (+)-26 was developed which is equipotent to clinical LTD4 antagonists Zafirlukast (1) and Pranlukast (2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93f7708327462fb74d92d363b9dcf20b
https://doi.org/10.1002/chin.199846153
https://doi.org/10.1002/chin.199846153
Autor:
T.C. Liston, Anthony Marfat, G.W. Antognoli, John B. Cheng, J.S. Pillar, Alexander V. Kuperman, J.T. Shirley, R. J. Chambers, Brian S. Owens, John W. Watson
Publikováno v:
ChemInform. 30
A new series of cysLT1 receptor antagonists represented by CP-288,886 (7) and CP-265,298 (8) were developed which are equipotent to clinical cysLT1 receptor antagonists Zafirlukast (1) and Pranlukast (2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8297659f8b15bdaa8123e6c9b39e8fa2
https://doi.org/10.1002/chin.199917137
https://doi.org/10.1002/chin.199917137
Autor:
G.W. Antognoli, C. Mebus, T.C. Liston, David B. Damon, R. J. Chambers, J. W. Watson, J.T. Shirley, A. Marfat, John B. Cheng, J.S. Pillar, Alexander V. Kuperman
Publikováno v:
Bioorganicmedicinal chemistry letters. 9(18)
CP-199,330 (3) and CP-199,331 (4) are cysLT1 receptor antagonists that are equipotent to marketed cysLT1 receptor antagonists zafirlukast and pranlukast, show good pharmacokinetics in rats and monkeys, and are devoid of liver toxicity in monkeys as s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a8f72c962989f6308e5d84259e1de6
https://pubmed.ncbi.nlm.nih.gov/10509933
https://pubmed.ncbi.nlm.nih.gov/10509933
Autor:
R. J. Chambers, Brian S. Owens, G.W. Antognoli, T.C. Liston, J.S. Pillar, Anthony Marfat, J.T. Shirley, John B. Cheng, Alexander V. Kuperman, John W. Watson
Publikováno v:
Bioorganicmedicinal chemistry letters. 8(24)
A new series of cysLT1 receptor antagonists represented by CP-288,886 (7) and CP-265,298 (8) were developed which are equipotent to clinical cysLT1 receptor antagonists Zafirlukast (1) and Pranlukast (2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::525d476901a89d7c912c0cf95eef1ecf
https://pubmed.ncbi.nlm.nih.gov/9934474
https://pubmed.ncbi.nlm.nih.gov/9934474